Figure 6.

TK⁺TC generate a GVL effect. All mice were given transplants as described in Materials and methods with 1 × 10⁷ bone marrow (BM) cells alone (●) or with 50 M1 leukemia cells (Leuk) (O) or with 4 × 10⁶ normal lymphocytes and 50 M1 leukemia cells (NL + Leuk, □) or with TK⁺TC (TK) without GCV (Δ), with GCV administered via an Alzet pump on days 10 through 16 (▲) after transplantation, with 50 M1 leukemia cells (Leuk) (◇) or with 50 leukemia cells and GCV administered via an Alzet pump on days 10 through 16 at a dose of 5 mg/wk (◆) or 0.5 mg/wk (*). Mice receiving TK⁺TC, leukemia cells, and GCV had a significantly longer survival times than did mice treated with TK⁺TC and leukemia cells without GCV (p = 0.002) but significantly shorter survival times than did mice receiving bone marrow alone (p = 0.02) or TK⁺TC and GCV without leukemia cells (p = 0.02). Results from seven experiments are combined. The number of mice treated is shown in stated in the legend. In the TK + Leuk + GCV 5-mg group, two mice are censored at 63 and 73 days and seven others survived >100 days.